Risk-adapted Treatment Strategy For COVID-19 Patients

Vista sencilla de ítem
dc.creatorZheng, Changcheng
dc.creatorWang, Jinquan
dc.creatorGuo, Hui
dc.creatorLu, Zhaohui
dc.creatorMa, Yan
dc.creatorZhu, Yuyou
dc.creatorXia, Daqing
dc.creatorWang, Yinzhong
dc.creatorHe, Hongliang
dc.creatorZhou, Jian
dc.creatorWang, Yong
dc.creatorFei, Mingming
dc.creatorYin, Yihong
dc.creatorZheng, Mao
dc.creatorXu, Yehong
dc.creatorAnhui Medical team members of National aid to prevent and treat novel coronavirus pneumonia in Wuhan
dc.date.accessioned2020-07-24T18:29:37Z
dc.date.available2020-07-24T18:29:37Z
dc.date.created2020-03-23
dc.description.abstractenglishBackground There are no clear expert consensus or guidelines on how to treat 2019 coronavirus disease (COVID-19). The objective of this study is to investigate the short-term effect of risk-adapted treatment strategy on patients with COVID-19. Methods We collected the medical records of 55 COVID-19 patients for analysis. We divided these patients into mild, moderate and severe groups, and risk-adapted treatment approaches were given according to the illness severity. Results Twelve patients were in mild group and 22 were in moderate group (non-severe group, n = 34), and 21 patients were in severe group. At the end of the first two weeks after admission, clinical manifestations had completely despeared in 31(91.2%)patients in non-severe group, and 18(85.7%) patients in severe group (p = 0.85). Both groups had a satisfied chest CT imaging recovery, which includes 22(64.7%) patients in non-severe group and 12(57.1%) patients in severe group recovered at least 50% of the whole leisions in the first week, and 28(82.4%) and 16(76.2%) recovered at least 75% in the second week, respectively. There were no significant differences in SARS-CoV-2 nucleic acid negativity (p = 0.92). There were also no significant differences in the levels of SARS-CoV-2-IgM and IgG antibody production between the two groups (p = 0.13, 0.62). There were 45 cases were discharged from the hospital, and no patients died at the time of this clinical analysis. Conclusions Risk-adapted treatment strategy was associated with significant clinical manifestations alleviation and clinical imaging recovery. In severe COVID-19 patients, early and short-term use of low-dose methylprednisolone was beneficial and did not delay SARS-CoV-2 nucleic acid clearance and influence IgG antibody production.spa
dc.format.extent4 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1016/j.ijid.2020.03.047spa
dc.identifier.issn1201-9712spa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S120197122030179X#kwd0005spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/11106
dc.publisherInternational Journal of Infectious Diseaseseng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectnovel coronavirus pneumoniaspa
dc.subjectrisk-adapted treatment strategyspa
dc.subjectantiviral treatmentspa
dc.subjectlow-dose corticosteroidspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleRisk-adapted Treatment Strategy For COVID-19 Patientsspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
Risk-adapted-Treatment-Strategy-For-COV_2020_International-Journal-of-Infect.pdf
Tamaño:
315.12 KB
Formato:
Adobe Portable Document Format
Descripción:
Documento Reservado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS